|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO006312039 |
| 003 |
DE-627 |
| 005 |
20230425181423.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2020 xx |||||o 00| ||und c |
| 035 |
|
|
|a (DE-627)WHO006312039
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001160-28-ES
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)MedOPP376
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a und
|
| 245 |
1 |
0 |
|a Tocilizumab plus Pembrolizumab in COVID-19
|b A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19 (COPERNICO Study)
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 13-04-2020, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Coronavirus Disease 2019 (COVID-19)-Pneumonia MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2020) vom: 20. Apr.
|
| 773 |
1 |
8 |
|g year:2020
|g day:20
|g month:04
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001160-28
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2020
|b 20
|c 04
|
Klinische Studie